Sadeer G Al-Kindi1, Anuja Sarode2, Melissa Zullo2, Sanjay Rajagopalan3, Mahboob Rahman4, Thomas Hostetter4, Mirela Dobre4. 1. Division of Cardiovascular Medicine, Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH. Electronic address: Sadeer.AlKindi@UHhospitals.org. 2. College of Public Health, Kent State University, Kent, OH. 3. Division of Cardiovascular Medicine, Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH. 4. Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH.
Abstract
OBJECTIVE: To assess the association between serum bicarbonate concentration and cause-specific mortality in the US general population. METHODS: A total of 31,195 individuals enrolled in the National Health and Nutrition Examination Survey between 1999 and 2010 were followed for a median 6.7 (interquartile range, 3.7-9.8) years. Cause-specific mortality was defined as cardiovascular, malignancy, and noncardiovascular/nonmalignancy causes. Cox proportional hazards adjusted for demographics, comorbidities, medications, and renal function were used to test the association between baseline serum bicarbonate and the outcomes of interest. RESULTS: Of the 2798 participants who died, 722 had a cardiovascular- and 620 had a malignancy-related death. Compared with participants with serum bicarbonate 22 to 26 mEq/L, those with a level below 22 mEq/L had an increased hazard of all-cause and malignancy-related mortality (hazard ratio [HR], 1.54; 95% CI, 1.30-1.83; and HR, 1.46; 95% CI 1.00-2.13, respectively). The hazard for cardiovascular mortality was increased by 8% with each 1 mEq/L increase in serum bicarbonate above 26 mEq/L (HR, 1.08; 95% CI, 1.01-1.15). The findings were consistent in participants with or without chronic kidney disease, with no significant interactions observed. CONCLUSION: In a large cohort of US adults, serum bicarbonate concentration level below 22 mEq/L was associated with malignancy-related mortality, whereas a concentration above 26 mEq/L was associated with cardiovascular mortality. Further studies to evaluate potential mechanisms for the differences in cause-specific mortality are warranted.
OBJECTIVE: To assess the association between serum bicarbonate concentration and cause-specific mortality in the US general population. METHODS: A total of 31,195 individuals enrolled in the National Health and Nutrition Examination Survey between 1999 and 2010 were followed for a median 6.7 (interquartile range, 3.7-9.8) years. Cause-specific mortality was defined as cardiovascular, malignancy, and noncardiovascular/nonmalignancy causes. Cox proportional hazards adjusted for demographics, comorbidities, medications, and renal function were used to test the association between baseline serum bicarbonate and the outcomes of interest. RESULTS: Of the 2798 participants who died, 722 had a cardiovascular- and 620 had a malignancy-related death. Compared with participants with serum bicarbonate 22 to 26 mEq/L, those with a level below 22 mEq/L had an increased hazard of all-cause and malignancy-related mortality (hazard ratio [HR], 1.54; 95% CI, 1.30-1.83; and HR, 1.46; 95% CI 1.00-2.13, respectively). The hazard for cardiovascular mortality was increased by 8% with each 1 mEq/L increase in serum bicarbonate above 26 mEq/L (HR, 1.08; 95% CI, 1.01-1.15). The findings were consistent in participants with or without chronic kidney disease, with no significant interactions observed. CONCLUSION: In a large cohort of US adults, serum bicarbonate concentration level below 22 mEq/L was associated with malignancy-related mortality, whereas a concentration above 26 mEq/L was associated with cardiovascular mortality. Further studies to evaluate potential mechanisms for the differences in cause-specific mortality are warranted.
Authors: Sankar D Navaneethan; Jesse D Schold; Susana Arrigain; Stacey E Jolly; Edgard Wehbe; Rupesh Raina; James F Simon; Titte R Srinivas; Anil Jain; Martin J Schreiber; Joseph V Nally Journal: Clin J Am Soc Nephrol Date: 2011-09-01 Impact factor: 8.237
Authors: Elise Schutte; Hiddo J Lambers Heerspink; Helen L Lutgers; Stephan J L Bakker; Priya Vart; Bruce H R Wolffenbuttel; Kausik Umanath; Julia B Lewis; Dick de Zeeuw; Ron T Gansevoort Journal: Am J Kidney Dis Date: 2015-05-16 Impact factor: 8.860
Authors: Mirela Dobre; Wei Yang; Jing Chen; Paul Drawz; L Lee Hamm; Edward Horwitz; Thomas Hostetter; Bernard Jaar; Claudia M Lora; Lisa Nessel; Akinlolu Ojo; Julia Scialla; Susan Steigerwalt; Valerie Teal; Myles Wolf; Mahboob Rahman Journal: Am J Kidney Dis Date: 2013-03-13 Impact factor: 8.860
Authors: Ian F Robey; Brenda K Baggett; Nathaniel D Kirkpatrick; Denise J Roe; Julie Dosescu; Bonnie F Sloane; Arig Ibrahim Hashim; David L Morse; Natarajan Raghunand; Robert A Gatenby; Robert J Gillies Journal: Cancer Res Date: 2009-03-10 Impact factor: 12.701
Authors: Mirela Dobre; Wei Yang; Qiang Pan; Lawrence Appel; Keith Bellovich; Jing Chen; Harold Feldman; Michael J Fischer; L L Ham; Thomas Hostetter; Bernard G Jaar; Radhakrishna R Kallem; Sylvia E Rosas; Julia J Scialla; Myles Wolf; Mahboob Rahman Journal: J Am Heart Assoc Date: 2015-04-20 Impact factor: 5.501